Futura Medical said a clinical trial of its erectile dysfunction treatment had not met its primary goals versus a placebo. The treatment, FM57, was compared to Futura's proprietary transdermal DermaSys formulation in the so-called phase three trial. At 10:05am: (LON:FUM) Futura Medical PLC share price was -18.95p at 10.05p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.